THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma

International Journal of Medical Sciences

Volumn 9, Issue 9, 2012, Pages 748-756

  Miki, Ikuya ^a,b   Nakamura, Tsutomu ^c,d   Kuwahara, Akiko ^c,e   Yamamori, Motohiro ^c,e   Nishiguchi, Kohshi ^c,f   Tamura, Takao ^a   Okuno, Tatsuya ^a   Omatsu, Hideaki ^c   Mizuno, Shigeto ^b   Hirai, Midori ^c   Azuma, Takeshi ^a   Sakaeda, Toshiyuki ^c,g  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^c KOBE UNIVERSITY   (Japan)

^d HIMEJI DOKKYO UNIVERSITY   (Japan)

^e MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^f KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^g KYOTO UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Esophageal squamous cell carcinoma; Prognosis; Severe acute toxicity; Thyroid hormone receptor beta

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; FLUOROURACIL; THYROID HORMONE RECEPTOR BETA;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CHEILITIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE SEVERITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; LEUKOPENIA; MALE; MUTATOR GENE; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; THYROID HORMONE RECEPTOR BETA GENE;

3' UNTRANSLATED REGIONS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CHEILITIS; CHEMORADIOTHERAPY; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GENE FREQUENCY; HAPLOTYPES; HUMANS; INTRONS; LEUKOPENIA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; STOMATITIS; THYROID HORMONE RECEPTORS BETA;

EID: 84868566642     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.5081     Document Type: Article

References (49)

1. [Internet] Cancer statistics in Japan. http://ganjoho.ncc.go.jp/public/statistics/backnumber/2010_en.html.
2. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009; 24: 729-735.
3. Sakaeda T, Yamamori M, Kuwahara A, et al. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv. Drug Deliv. Rev. 2009; 61: 388-401.
4. Kranzfelder M, Buchler P, Lange K, et al. Treatment options for squamous cell cancer of the esophagus: a systematic review of the literature. J. Am. Coll. Surg. 2010; 210: 351-359.
5. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J. Clin. Oncol. 1999; 17: 2915-2921.
6. Kaneko K, Ito H, Konishi K, et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br. J. Cancer. 2003; 88: 18-24.
7. Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int. J. Radiat. Oncol. Biol. Phys. 2011; 81: 684-690.
8. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents CA Cancer J. Clin. 2009; 59: 42-55.
9. O'Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol. 2012; 6: 251-259.
10. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr. Rev. 2010; 31: 139-70.
11. Moreno M, de Lange P, Lombardi A, et al. Metabolic effects of thyroid hormone derivatives. Thyroid. 2008; 18: 239-253.
12. Jones I, Ng L, Liu H, Forrest D. An intron control region differentially regulates expression of thyroid hormone receptor beta2 in the cochlea, pituitary, and cone photoreceptors. Mol. Endocrinol. 2007; 21: 1108-1119.
13. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 2001; 81: 1097-1142.
14. Kress E, Samarut J, Plateroti M. Thyroid hormones and the control of cell proliferation or cell differentiation: paradox or duality? Mol. Cell Endocrinol. 2009; 313: 36-49.
15. Axelrod AR, Berman L. The bone marrow in hyperthyroidism and hypothyroidism. Blood. 1951; 6: 436-453.
16. Foster MP, Montecino-Rodriguez E, Dorshkind K. Proliferation of bone marrow pro-B cells is dependent on stimulation by the pituitary/thyroid axis. J. Immunol. 1999; 163: 5883-5890.
17. Grymula K, Paczkowska E, Dziedziejko V, et al. The influence of 3,3',5-triiodo-L-thyronine on human haematopoiesis. Cell Prolif. 2007; 40: 302-315.
18. Kawa MP, Grymula K, Paczkowska E, et al. Clinical relevance of thyroid dysfunction in human haematopoiesis: biochemical and molecular studies. Eur. J. Endocrinol. 2010; 162: 295-305.
19. Cheng SY. Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev. Endocr. Metab. Disord. 2000; 1: 9-18.
20. Matsuse M, Saenko V, Sedliarou I, et al. A novel role for thyroid hormone receptor beta in cellular radiosensitivity. J. Radiat. Res (Tokyo). 2008; 49: 17-27.
21. Kowalik MA, Perra A, Pibiri M, et al. TRbeta is the critical thyroid hormone receptor isoform in T3-induced proliferation of hepatocytes and pancreatic acinar cells. J. Hepatol. 2010; 53: 686-692.
22. Lopez-Fontal R, Zeini M, Traves PG, et al. Mice lacking thyroid hormone receptor Beta show enhanced apoptosis and delayed liver commitment for proliferation after partial hepatectomy. PLoS One. 2010; 5: e8710.
23. Flores-Morales A, Gullberg H, Fernandez L, et al. Patterns of liver gene expression governed by TRbeta. Mol. Endocrinol. 2002; 16: 1257-1268.
24. Ornellas Ddos S, Gomes AC, Santiago LA, et al. Thyroid hormone beta receptor mutation causes renal dysfunction and impairment of ClC-2 chloride channel expression in mouse kidney. Cell Physiol. Biochem. 2010; 26: 227-234.
25. Plevová P. Prevention and treatment of chemotherapy and radiotherapy-induced oral mucositis: a review. Oral Oncol. 1999; 35: 453-470.
26. Kosugi S, Sasamoto R, Kanda T, et a. Retrospective review of surgery and definitive chemoradiotherapy in patients with squamous cell carcinoma of the thoracic esophagus aged 75 years or older. Jpn. J. Clin. Oncol. 2009; 39: 360-366.
27. Miki I, Tamura T, Nakamura T, et al. Circadian variability of pharmaco-kinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. Ther. Drug Monit. 2005; 27: 369-374.
28. Okuno T, Tamura T, Yamamori M, et al. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese. Am. J. Clin. Oncol. 2007; 30: 252-257.
29. Sakaeda T, Yamamori M, Kuwahara A, et al. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. Ther. Drug Monit. 2008; 30: 497-503.
30. Kuwahara A, Yamamori M, Fujita M, et al. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J. Exp. Clin. Cancer Res. 2010; 29: 100.
31. [Internet] dbSNP. http://www.ncbi.nlm.nih.gov/projects/SNP/
32. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 2001; 68: 978-89.
33. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 2003; 73: 1162-1169.
34. Komoto C, Nakamura T, Sakaeda T, et al. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab. Pharmacokinet. 2006; 21: 126-132.
35. Markova S, Nakamura T, Makimoto H, et al. IL-1beta genotype-related effect of prednisolone on IL-1beta production in human peripheral blood mononuclear cells under acute inflammation. Biol. Pharm. Bull. 2007; 30: 1481-1487.
36. Refetoff S, Dumitrescu AM. Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination. Best Pract. Res. Clin. Endocrinol. Metab. 2007; 21: 277-305.
37. Gonzalez-Sancho JM, Garcia V, Bonilla F, et al. Thyroid hormone receptors/THR genes in human cancer. Cancer Lett. 2003; 192: 121-132.
38. Aranda A, Martinez-Iglesias O, Ruiz-Llorente L, et al. Thyroid receptor: roles in cancer. Trends Endocrinol. Metab. 2009; 20: 318-324.
39. Pastinen T, Hudson TJ. Cis-acting regulatory variation in the human genome. Science. 2004; 306: 647-650.
40. Frankton S, Harvey CB, Gleason LM, et al. Multiple messenger ribonucleic acid variants regulate cell-specific expression of human thyroid hormone receptor beta1. Mol. Endocrinol. 2004; 18: 1631-1642.
41. Master A, Wojcicka A, Piekielko-Witkowska A, et al. Untranslated regions of thyroid hormone receptor beta 1 mRNA are impaired in human clear cell renal cell carcinoma. Biochim. Biophys. Acta. 2010; 1802: 995-1005.
42. Puzianowska-Kuznicka M, Pietrzak M, Turowska O, et al. Thyroid hormones and their receptors in the regulation of cell proliferation. Acta. Biochim. Pol. 2006; 53: 641-650.
43. Amorim BS, Ueta CB, Freitas BC, et al. A TRbeta-selective agonist con-fers resistance to diet-induced obesity. J. Endocrinol. 2009; 203: 291-299.
44. Alberobello AT, Congedo V, Liu H, et al. An intronic SNP in the thyroid hormone receptor beta gene is associated with pituitary cell-specific over-expression of a mutant thyroid hormone receptor beta2 (R338W) in the index case of pituitary-selective resistance to thyroid hormone. J. Transl. Med. 2011; 9: 144.
45. Gloire G, Erneux C, Piette J. The role of SHIP1 in T-lymphocyte life and death. Biochem. Soc. Trans. 2007; 35: 277-280.
46. Moeller LC, Haselhorst NE, Dumitrescu AM, et al. Stanniocalcin 1 induction by thyroid hormone depends on thyroid hormone receptor beta and phosphatidylinositol 3-kinase activation. Exp. Clin. Endocrinol. Diabetes. 2011; 119: 81-85.
47. Furuya F, Lu C, Guigon CJ, et al. Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors. Steroids. 2009; 74: 628-634.
48. Boomsma MJ, Bijl HP, Langendijk JA. Radiation-induced hypothyroidism in head and neck cancer patients: a systematic review. Radiother. Oncol. 2011; 99: 1-5.
49. van Santen HM, Thonissen NM, de Kraker J, et al. Changes in thyroid hormone state in children receiving chemotherapy. Clin. Endocrinol (Oxf). 2005; 62: 250-257.